MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT06626230 | RECRUITING | PHASE1
48 participants

Safety of Anal Curcumin

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-18
Start Date:
2025-03-17
Completion:
2026-12-31
Conditions
  • Anal High Grade Squamous Intraepithelial Lesion
Interventions
  • DRUG
No Results Yet
NCT06581263 | COMPLETED
10 participants

Psychedelic Virtual Reality

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-18
Start Date:
2025-07-22
Completion:
2026-03-22
Conditions
  • Psychedelic Experiences
  • Virtual Reality
  • Healthy Volunteer
Interventions
  • DEVICE
No Results Yet
NCT06564844 | ACTIVE_NOT_RECRUITING | PHASE3
25 participants

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-18
Start Date:
2024-10-15
Completion:
2027-06-30
Conditions
  • Non-small Cell Lung Cancer
Interventions
  • DRUG
No Results Yet
NCT06507579 | RECRUITING
250 participants

Hydra Registry - UK

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-18
Start Date:
2024-07-11
Completion:
2027-07-11
Conditions
  • Aortic Valve Stenosis
Interventions
  • DEVICE
No Results Yet
NCT06484153 | RECRUITING | PHASE2
25 participants

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-18
Start Date:
2024-07-22
Completion:
2026-07-22
Conditions
  • To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
  • To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer
  • Combination of Fruquintinib and Anti-PD-1 Antibody Was Reported to Improve Patient Prognosis in Colorectal Cancer
Interventions
  • DRUG
No Results Yet
NCT06479811 | RECRUITING | PHASE1
120 participants

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-18
Start Date:
2025-08-19
Completion:
2029-01-01
Conditions
  • Sinonasal Neuroendocrine Carcinoma
  • Nasopharyngeal Carcinoma
  • Esthesioneuroblastoma
  • Olfactory Neuroblastoma
  • Somatostatin Receptor Positive
  • Small Cell Lung Cancers
  • Pheochromocytoma/Paragangliomas
  • Kidney Cancers
  • Head and Neck Tumors
  • Gastrointestinal Neuroendocrine Tumors
Interventions
  • DRUG
No Results Yet
NCT06427798 | RECRUITING | PHASE1/PHASE2
66 participants

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-18
Start Date:
2025-02-07
Completion:
2029-07-01
Conditions
  • Somatostatin Receptor Positive
  • Gastrointestinal Neuroendocrine Tumors
  • Pheochromocytoma
  • Paragangliomas
Interventions
  • DRUG
No Results Yet
NCT06416072 | ENROLLING_BY_INVITATION
3000 participants

Alzheimer's Plasma Extension

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-18
Start Date:
2023-09-21
Completion:
2028-06-30
Conditions
  • Preclinical Alzheimer's Disease
  • Alzheimer's Disease (AD)
Interventions
  • RADIATION
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page